EFFICACY OF AEROSOLIZED TOBRAMYCIN IN PATIENTS WITH CYSTIC-FIBROSIS
EFFICACY OF AEROSOLIZED TOBRAMYCIN IN PATIENTS WITH CYSTIC-FIBROSIS
复制标题
DOI：
10.1056/nejm199306173282403
复制
发表时间：
1993-06-17
影响因子：
158.5
通讯作者：
SMITH, AL
中科院分区：
文献类型：
--
作者：
RAMSEY, BW;DORKIN, HL;SMITH, AL
Background Direct aerosol delivery of aminoglycosides such as tobramycin to the lower airways of patients with cystic fibrosis may control infection with Pseudomonas aeruginosa and improve pulmonary function, with low systemic toxicity. We conducted a randomized crossover study to evaluate the safety and efficacy of aerosolized tobramycin in patients with cystic fibrosis and P. aeruginosa infections.Methods. Seventy-one patients with stable pulmonary status were recruited from seven U.S. centers for the treatment of cystic fibrosis and randomly assigned to one of two crossover regimens. Group 1 received 600 mg of aerosolized tobramycin for 28 days, followed by half-strength physiologic saline (placebo) for two 28-day periods. Group 2 received placebo for 28 days, followed by tobramycin for two 28-day periods. Pulmonary function, the density of P. aeruginosa in sputum, ototoxicity, nephrotoxicity, and the emergence of tobramycin-resistant P. aeruginosa were monitored.Results. In the first 28-day period, treatment with tobramycin was associated with an increase in the percentage of the value predicted for forced expiratory volume in one second (9.7 percentage points higher than the value for placebo; P
